Credit Industriel ET Commercial acquired a new stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV - Free Report) in the fourth quarter, according to its most recent disclosure with the SEC. The firm acquired 150,000 shares of the company's stock, valued at approximately $1,774,000.
Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Norges Bank purchased a new stake in shares of Roivant Sciences during the 4th quarter worth approximately $52,443,000. Invesco Ltd. lifted its position in Roivant Sciences by 49.7% during the fourth quarter. Invesco Ltd. now owns 9,515,058 shares of the company's stock valued at $112,563,000 after purchasing an additional 3,159,603 shares during the last quarter. Vanguard Group Inc. grew its stake in shares of Roivant Sciences by 5.8% in the 4th quarter. Vanguard Group Inc. now owns 44,087,287 shares of the company's stock worth $521,553,000 after buying an additional 2,404,232 shares in the last quarter. Marshall Wace LLP grew its stake in shares of Roivant Sciences by 104.4% in the 4th quarter. Marshall Wace LLP now owns 2,946,954 shares of the company's stock worth $34,862,000 after buying an additional 1,505,062 shares in the last quarter. Finally, Pertento Partners LLP increased its holdings in shares of Roivant Sciences by 22.8% in the 4th quarter. Pertento Partners LLP now owns 3,484,918 shares of the company's stock worth $41,227,000 after buying an additional 646,865 shares during the last quarter. Institutional investors own 64.76% of the company's stock.
Roivant Sciences Trading Up 1.6 %
Shares of ROIV traded up $0.18 during midday trading on Monday, hitting $11.19. 8,301,359 shares of the company's stock traded hands, compared to its average volume of 5,473,404. The stock has a market capitalization of $7.98 billion, a price-to-earnings ratio of -74.60 and a beta of 1.25. The firm's fifty day moving average is $10.34 and its 200-day moving average is $11.14. Roivant Sciences Ltd. has a 1 year low of $8.73 and a 1 year high of $13.06.
Roivant Sciences (NASDAQ:ROIV - Get Free Report) last posted its quarterly earnings results on Monday, February 10th. The company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.24) by $0.04. Roivant Sciences had a negative net margin of 119.54% and a negative return on equity of 14.05%. On average, equities research analysts anticipate that Roivant Sciences Ltd. will post -0.92 EPS for the current year.
Wall Street Analysts Forecast Growth
ROIV has been the topic of several recent research reports. Cantor Fitzgerald upgraded Roivant Sciences to a "strong-buy" rating in a report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $18.00 target price on shares of Roivant Sciences in a report on Monday, April 21st.
Check Out Our Latest Analysis on ROIV
Insider Buying and Selling at Roivant Sciences
In related news, CAO Rakhi Kumar sold 227,500 shares of the stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $10.43, for a total transaction of $2,372,825.00. Following the completion of the transaction, the chief accounting officer now owns 163,264 shares of the company's stock, valued at approximately $1,702,843.52. This trade represents a 58.22 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, COO Eric Venker sold 218,041 shares of Roivant Sciences stock in a transaction on Thursday, February 13th. The shares were sold at an average price of $10.42, for a total value of $2,271,987.22. Following the completion of the sale, the chief operating officer now directly owns 896,869 shares of the company's stock, valued at $9,345,374.98. The trade was a 19.56 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 1,395,541 shares of company stock valued at $14,922,538 over the last ninety days. Corporate insiders own 7.90% of the company's stock.
Roivant Sciences Profile
(
Free Report)
Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.
Featured Stories
Before you consider Roivant Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Roivant Sciences wasn't on the list.
While Roivant Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
